Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients
The purpose of this study is to Evaluate and compare safety and efficacy of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients Receiving Etoposide Combined With Platinum Based First-line Chemotherapy
Small Cell Lung Cancer
DRUG: gemcitabine|OTHER: observation group
Progression-free survival (PFS), from the first cycle of treatment (day one) to two month after the last cycle
from the first cycle of treatment (day one) to two month after the last cycle